POCI PRECISION OPTICS CORPORATION, INC.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 867840 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY53.0%
TTM net income YoY59.6%
TTM EPS YoY69.4%
Revenue 3-yr CAGR17.6%
Net income 3-yr CAGR—
Margins
Gross margin19.2%
Operating margin-7.4%
Net margin-7.5%
FCF margin—
EBITDA margin-6.5%
Returns
ROE-15.9%
ROA-9.3%
ROIC (approx.)-16.3%
Asset turnover1.25x
Leverage & solvency
Liabilities / assets34.0%
Debt / equity0.06x
Current ratio2.46x
Interest coverage-17.82x
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-0.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $31.53M | $19.09M | $19.10M | $21.04M | $15.68M |
| Cost of revenue | $26.10M | $15.69M | $13.31M | $13.31M | $10.75M |
| Gross profit | $5.43M | $3.40M | $5.80M | $7.73M | $4.93M |
| R&D expense | $1.03M | $1.16M | $981,781 | $992,375 | $666,479 |
| SG&A expense | $7.91M | $7.80M | $7.54M | $7.38M | $5.61M |
| Operating income | -$3.51M | -$5.55M | -$2.72M | -$638,548 | -$1.51M |
| Interest expense | $148,129 | $227,019 | $225,108 | $218,927 | $155,658 |
| Pretax income | -$3.62M | -$5.78M | -$2.95M | -$142,677 | -$927,464 |
| Income tax | $4,958 | $1,936 | $1,936 | $1,936 | $952 |
| Net income | -$3.63M | -$5.78M | -$2.95M | -$144,613 | -$928,416 |
| EBITDA | -$3.23M | -$5.34M | -$2.51M | -$427,813 | -$1.32M |
| EPS (basic) | -0.43 | -0.85 | -0.49 | -0.03 | -0.18 |
| EPS (diluted) | -0.43 | -0.85 | -0.49 | -0.03 | -0.18 |
| Weighted avg. shares (diluted) | 8.53M | 6.79M | 6.07M | 5.67M | 5.30M |
| Balance sheet | |||||
| Cash & equivalents | $9.84M | $1.77M | $405,278 | $2.93M | $605,749 |
| Receivables | $5.94M | $4.34M | $3.55M | $3.91M | $2.66M |
| Inventory | $3.83M | $3.56M | $2.87M | $2.78M | $3.02M |
| Current assets | $20.11M | $10.06M | $7.12M | $9.86M | $6.51M |
| PP&E, net | $887,713 | $533,792 | $493,573 | $433,520 | $627,471 |
| Goodwill | $8.82M | $8.82M | $8.82M | $8.82M | $8.82M |
| Intangibles | $212,889 | $232,493 | $286,559 | $265,111 | $229,398 |
| Total assets | $32.34M | $19.79M | $16.91M | $19.74M | $16.70M |
| Current liabilities | $8.83M | $6.15M | $4.91M | $5.26M | $4.59M |
| Short-term debt | $577,898 | $577,898 | $276,928 | $513,259 | $367,714 |
| Long-term debt | $711,305 | $1.29M | $1.90M | $2.18M | $1.96M |
| Total debt | $1.29M | $1.87M | $2.18M | $2.69M | $2.33M |
| Total liabilities | $11.99M | $7.53M | $6.84M | $7.69M | $7.73M |
| Shareholders' equity | $20.35M | $12.26M | $10.07M | $12.05M | $8.97M |
| Net debt | -$8.55M | $93,368 | $1.77M | -$236,613 | $1.72M |
| Shares outstanding | 10.97M | 7.71M | 6.07M | 6.07M | 5.64M |
| Cash flow statement | |||||
| Operating cash flow | -$1.55M | -$3.40M | -$2.68M | -$81,090 | -$933,371 |
| Capital expenditure | $426,786 | $227,209 | $272,435 | $16,784 | $113,197 |
| Free cash flow | -$1.98M | -$3.62M | -$2.96M | -$97,874 | -$1.05M |
| Investing cash flow | -$429,350 | -$233,473 | -$293,883 | -$52,497 | -$407,802 |
| Financing cash flow | $10.05M | $5.00M | $456,321 | $2.45M | $1.09M |
| Depreciation & amortization | $279,277 | $212,439 | $212,382 | $210,735 | $190,221 |
| Stock-based compensation | $1.14M | $1.61M | $959,784 | $919,032 | $915,494 |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.